Workforce & capacity

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Europe Has Plans. Implementation Is Lagging

A Self-Guided Pathway for Functional Seizures

Ebola’s Vaccine Trial Enters New Territory

The Mystery Patient Found The Gaps

Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own

Preparedness Finally Has Capital

Why rural cardiology needs more than another recruitment drive

Precision Oncology Has a Scale Problem

Food Safety Gets A Political Upgrade
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
